Ribomic Inc.
Notice of Progress and Contract Extension for Collaborative Research with the University of Tokyo
Reported nonclinical evaluation results of aptamer targeting RBM-006 for ocular diseases. Confirmed potential for lowering intraocular pressure, inhibiting angiogenesis, and anti-inflammatory effects in relation to glaucoma and retinal diseases. Joint research period extended to March 2027 with no increase in costs. Expectation of expanded license opportunities and value enhancement of the pipeline in the future.
Key Figures
- RBM-006: Efficacy confirmed in nonclinical models
- Joint research period extended: to March 2027
- No increase in joint research costs
AI要約
News Overview
Ribomic announces progress of joint research with the Department of Ophthalmology, University of Tokyo, reporting that nonclinical evaluation of aptamer drugs centered on RBM-006 shows significant pharmacological efficacy for ocular diseases. In particular, three key pharmacological actions—reduction of intraocular pressure, inhibition of angiogenesis, and anti-inflammatory effects—have been confirmed. This is expected to broaden applications across many ophthalmic disease areas and to increase future license opportunities. The joint research period has been extended to March 2027, with no increase in costs.
Impact and Outlook
This development is positioned as a significant advancement that enhances the pipeline value for the company’s focus area of ophthalmic diseases in clinical development. Indications of cross-aptamer efficacy suggest opportunities for expansion into large markets such as glaucoma, age-related macular degeneration, and diabetic retinopathy, and expect expansion of license agreements and partnerships. There is no cost increase due to contractual changes; only the research period has been extended.
Ribomic Inc.
Company overview · Stock price · Financial data · All IR
